CINECA IRIS Institutional Research Information System

LORUSSO, LOREDANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.222
EU - Europa 1.326
AS - Asia 1.105
SA - Sud America 192
AF - Africa 76
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.929
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.173
IT - Italia 396
SG - Singapore 368
DE - Germania 335
CN - Cina 331
HK - Hong Kong 176
SE - Svezia 170
BR - Brasile 152
GB - Regno Unito 108
AT - Austria 77
BG - Bulgaria 68
VN - Vietnam 48
RU - Federazione Russa 43
IN - India 36
CA - Canada 32
FI - Finlandia 32
FR - Francia 28
JP - Giappone 27
CI - Costa d'Avorio 26
TR - Turchia 25
KR - Corea 20
SN - Senegal 20
MA - Marocco 18
NL - Olanda 13
AR - Argentina 12
IQ - Iraq 12
PL - Polonia 12
BD - Bangladesh 11
MX - Messico 11
PH - Filippine 9
UA - Ucraina 8
CL - Cile 7
UZ - Uzbekistan 7
ZA - Sudafrica 7
CH - Svizzera 6
AU - Australia 5
CO - Colombia 5
EC - Ecuador 5
ES - Italia 5
LT - Lituania 5
CZ - Repubblica Ceca 4
ID - Indonesia 4
IR - Iran 4
PK - Pakistan 4
RO - Romania 4
UY - Uruguay 4
VE - Venezuela 4
IL - Israele 3
KZ - Kazakistan 3
SA - Arabia Saudita 3
EE - Estonia 2
EG - Egitto 2
LB - Libano 2
MY - Malesia 2
NP - Nepal 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A1 - Anonimo 1
BE - Belgio 1
BH - Bahrain 1
BO - Bolivia 1
DK - Danimarca 1
GA - Gabon 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IE - Irlanda 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KI - Kiribati 1
MM - Myanmar 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PY - Paraguay 1
QA - Qatar 1
SR - Suriname 1
SY - Repubblica araba siriana 1
Totale 4.929
Salva come PNG Salva come JPEG
Città #
Ashburn 302
Dallas 236
Singapore 200
Hong Kong 175
Chandler 174
Milan 173
Fairfield 149
Santa Clara 130
Woodbridge 130
Seattle 86
Houston 85
New York 78
Shanghai 76
Vienna 73
Sofia 67
Beijing 54
Cambridge 54
Los Angeles 54
Wilmington 54
Ann Arbor 52
Munich 50
London 39
Hefei 37
Princeton 36
Florence 35
Boardman 33
Rome 28
Abidjan 26
Frankfurt am Main 25
Lawrence 25
Dearborn 22
Bremen 20
Dakar 20
Medford 20
Seoul 19
São Paulo 18
Tokyo 18
Pisa 17
Turku 17
Redondo Beach 16
Ottawa 13
Casablanca 12
Dong Ket 12
Redwood City 12
Denver 11
Ho Chi Minh City 11
San Diego 11
Serra 11
Des Moines 10
Nanjing 10
Phoenix 10
Warsaw 10
Fuzhou 9
Nuremberg 9
Washington 9
Istanbul 8
Ogden 8
Orem 8
Atlanta 7
Baghdad 7
Council Bluffs 7
Lancaster 7
Montreal 7
Quanzhou 7
Toronto 7
Belo Horizonte 6
Brooklyn 6
Buffalo 6
Chicago 6
Helsinki 6
Izmir 6
Nanchang 6
Redmond 6
Salt Lake City 6
Scandicci 6
Shenyang 6
Tashkent 6
Ankara 5
Boston 5
Chiesina Uzzanese 5
Johannesburg 5
Stockholm 5
Tianjin 5
Bern 4
Brno 4
Chengdu 4
Cleveland 4
Dhaka 4
Düsseldorf 4
Guangzhou 4
Paris 4
Porto Alegre 4
Quito 4
San Jose 4
Santiago 4
Xiamen 4
Amsterdam 3
Bangalore 3
Boulder 3
Changsha 3
Totale 3.322
Salva come PNG Salva come JPEG
Nome #
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 225
Targeted Therapy in Thyroid Cancer: State of the Art 211
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 207
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 201
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 200
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 192
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 186
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 185
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 184
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 183
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 176
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 175
Il carcinoma tiroideo: nuove prospettive terapeutiche. 172
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 170
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 163
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 152
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 151
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 147
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 145
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 145
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 141
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 139
Carcinoma tiroideo e gravidanza. 131
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 130
null 122
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 114
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 113
Ret mutated C-cells proliferate more rapidly than non-mutated neoplastic cells 111
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 110
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 103
Hand-foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer 73
null 70
null 54
Risultati dello studio di fase III, randomizzato, controllato, in doppio cieco, Sorafenib vs Placebo nel trattamento del carcinoma differenziato della tiroide (CDT) localmente avanzato o metastatico, refrattario al 131I, in progressione. 35
Totale 5.016
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.024
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.024
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021135 0 0 0 0 0 31 6 12 19 16 18 33
2021/2022318 19 6 2 13 62 47 10 16 25 19 22 77
2022/2023653 73 104 53 65 63 76 6 36 105 14 48 10
2023/2024519 60 70 78 47 67 87 19 8 6 7 22 48
2024/20251.198 9 42 13 64 121 106 108 65 113 144 138 275
2025/20261.089 162 266 170 183 183 125 0 0 0 0 0 0
Totale 5.016